Orphan Suite

Marketing research and forecasting tools to support your compound from Phase I to loss of exclusivity

Marketing research for orphan and ultra-orphan drugs presents several unique challenges:

  • Small sample sizes, which make conventional quantitative research methods extremely challenging to execute
  • Passionate and diffuse stakeholders, including parents seeking to give their children the best lives possible and collateral health professionals such as dietitians and genetics counselors who become the trusted advisors to their patients
  • Fast, high-impact financial decisions, often related to licensing and acquisition or investment in hard-to-execute clinical trials

RG+A’s combination of small sample methods, multi-stage techniques, and modeling tools provides a toolkit of services designed to meet your major challenges throughout the product life cycle.

  • Qualitative to Modeling®: Qualitative-to-Modeling links qualitative interviews to a Monte Carlo Model to generate robust estimates from small samples and calculate probability of success. This enables accurate forecasts and evaluations with the limited sample sizes available in orphan drug research.
  • Qualitative Conjoint: Qualitative Conjoint enables our clients to conduct trade-off exercises even when the available sample is not sufficient for quantitative research. Statistical techniques such as bootstrapping increase the precision of the conjoint estimates, and such a study even enables our clients to identify segments within the sample.
  • PV Scope: PVScope relies on iteration and respondent dialogue to maximize the insights provided by very small samples. Our orphan drug clients use PV Scope when they need deep insights fast and with very limited samples.
  • Contract Simulation®: Since contracting often plays a key role in orphan drug access and success, an effective contracting strategy is critical. Contract Simulation informs both an optimal contracting strategy and an optimal negotiation strategy by simulating contract negotiations with stakeholders, providing a realistic test our clients can observe.
  • Co-creation: Our clients often need to develop programs (be they clinical, financial or educational) and trials that they can be confident will be effective. Our co-creation methods bring together researchers, client representatives and stakeholders to jointly create a program that is feasible and acceptable to everyone involved.